NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:33 AM
Galmed Pharmaceuticals Ltd reports results for the quarter ended June 30 - Earnings Summary
Galmed Pharmaceuticals Ltd expected to post a loss of $3.12 a share - Earnings Preview
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Galmed Announces First Time Results In Prostate Oncology Studies Aramchol Demonstrates 3-4 Fold Increase In Cell Death Compared To Enzalutamide Alone In Prostate Cancer Models
Brief: Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms For Colospan Ltd.
Brief: Galmed Announces Results From First-In-Man Pharmacokinetics Study Of Oral Formulation Of Aramchol Meglumine (Am) 400Mg Am Increases Bioavailability By ~500% In Comparison To Aramchol Free Acid (Aa) 300Mg
U.S. STOCKS ON THE MOVE-BlackRock, MDA Space, Revolution Medicines
U.S. STOCKS ON THE MOVE-Bloom, J&J, CarMax
U.S. STOCKS ON THE MOVE-Tesla, Nano-X, Travere
Galmed rises as it teams up to test brain cancer drug
U.S. STOCKS ON THE MOVE-Amazon, Northrop Grumman, Brown-Forman
U.S. STOCKS ON THE MOVE-Zscaler, Carlyle, Weight Watchers
U.S. STOCKS ON THE MOVE-Marvell Technology, Tempus AI, Energy Vault
Galmed jumps on lab data on new brain-penetrating version of experimental drug
Brief: Galmed Announces Grant Of New Use Patents For The Combination Of Aramchol And Madrigal Pharmaceuticals
U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Energizer Holdings, Target